Eli Lilly shares have room to keep going as GLP-1 drugs spread their reach.

Eli Lilly shares rose again Tuesday, their sixth increase in the past seven sessions. The drugmaker's market cap also closed ...

Sen. Ruben Gallego (D-Ariz.) is asking for more information on Eli Lilly’s recently announced agreement with the Trump ...

LLY???s newest approvals and pipeline deals add fresh momentum to revenue growth as the company expands beyond its GLP-1 ...

Eli Lilly's tirzepatide acts on two hormonal pathways, so it's called a dual GIP/GLP-1 receptor agonist, and it entered the ...

Apple became the first $1 trillion company on U.S. public markets in 2018. Six of the eight companies to follow in Apple’s ...

MoneyFlows data shows how Big Money investors are again betting heavily on the stock. Institutional volumes reveal plenty. In ...

Let’s delve into the details of each of the evaluated factors, but first, for a quick background: With a $917 Bil market cap, ...

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. Eli Lilly has advanced in the triple-digits ...

Eli Lilly stock has regained all-time highs, outpacing rivals in the obesity drug market. Click here to read my latest ...

Eli Lilly & Co. is bringing a pharmaceutical startup incubator to 2300 Market St. MCB Science + Health has finished the ...

If Eli Lilly's obesity pill orforglipron is approved and priced around $200 per month, analysts at Truist predict patients ...